Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
Philip A. Philip(Wayne State University), Pascal Hammel(Hôpital Paul-Brousse), Roberto Pazo-Cid(Hospital Universitario Miguel Servet), Jamil Asselah(McGill University), Christophe Borg(Centre Hospitalier Universitaire de Besançon), Eric Terrebonne(Hôpital Cardiologique du Haut-Lévêque), Jill Lacy(Smilow Cancer Hospital), Teng Jin Ong, Muhammad Wasif Saif(Wayne State University), Ahmed Zakari(Florida Hospital Cancer Institute), Javier Sastre(Hospital Clínico San Carlos), Fernando Rivera(Marqués de Valdecilla University Hospital), Alberto F. Sobrero(Ospedale Policlinico San Martino), Edward Kim(University of California, Davis), Jack Shiansong Li, Scot Dowden, José Luis Manzano Mozo(Sorbonne Université), Venu Bathini(UMass Memorial Health Care), Thomas Nydam, Fabienne Portales(Institut de Recherche en Cancérologie de Montpellier), Daniel López‐Trabada
Cited by 249
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914